Henrickson Nauta Wealth Advisors Inc. Has $991,000 Position in Gilead Sciences, Inc. $GILD

Henrickson Nauta Wealth Advisors Inc. lessened its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 49.6% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 7,112 shares of the biopharmaceutical company’s stock after selling 7,013 shares during the period. Henrickson Nauta Wealth Advisors Inc.’s holdings in Gilead Sciences were worth $991,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also made changes to their positions in GILD. Paulson Wealth Management Inc. raised its position in Gilead Sciences by 1.8% during the fourth quarter. Paulson Wealth Management Inc. now owns 3,887 shares of the biopharmaceutical company’s stock valued at $477,000 after purchasing an additional 67 shares in the last quarter. Essex Financial Services Inc. boosted its holdings in shares of Gilead Sciences by 0.9% in the 4th quarter. Essex Financial Services Inc. now owns 7,724 shares of the biopharmaceutical company’s stock valued at $948,000 after purchasing an additional 71 shares in the last quarter. Alpha Cubed Investments LLC boosted its holdings in shares of Gilead Sciences by 1.1% in the 4th quarter. Alpha Cubed Investments LLC now owns 6,619 shares of the biopharmaceutical company’s stock valued at $812,000 after purchasing an additional 75 shares in the last quarter. Personal CFO Solutions LLC increased its stake in shares of Gilead Sciences by 1.7% in the 4th quarter. Personal CFO Solutions LLC now owns 4,572 shares of the biopharmaceutical company’s stock valued at $561,000 after purchasing an additional 76 shares during the last quarter. Finally, Moss Adams Wealth Advisors LLC increased its stake in shares of Gilead Sciences by 1.7% in the 4th quarter. Moss Adams Wealth Advisors LLC now owns 4,446 shares of the biopharmaceutical company’s stock valued at $546,000 after purchasing an additional 76 shares during the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Insider Transactions at Gilead Sciences

In related news, CEO Daniel Patrick O’day sold 15,000 shares of the stock in a transaction on Monday, June 1st. The stock was sold at an average price of $131.46, for a total value of $1,971,900.00. Following the completion of the sale, the chief executive officer directly owned 617,567 shares in the company, valued at $81,185,357.82. This represents a 2.37% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the firm’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of $125.40, for a total value of $376,200.00. Following the transaction, the chief financial officer directly owned 171,646 shares of the company’s stock, valued at approximately $21,524,408.40. This represents a 1.72% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 68,000 shares of company stock worth $8,930,150. Company insiders own 0.30% of the company’s stock.

Gilead Sciences Stock Performance

NASDAQ:GILD opened at $123.76 on Monday. The stock’s 50-day moving average is $131.66 and its 200-day moving average is $134.28. Gilead Sciences, Inc. has a 1-year low of $104.46 and a 1-year high of $157.29. The company has a current ratio of 1.97, a quick ratio of 1.77 and a debt-to-equity ratio of 0.89. The stock has a market cap of $153.66 billion, a P/E ratio of 16.86 and a beta of 0.31.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.91 by $0.12. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The business had revenue of $6.96 billion during the quarter, compared to analyst estimates of $6.91 billion. During the same quarter last year, the business earned $1.81 EPS. The firm’s quarterly revenue was up 4.4% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. Equities research analysts anticipate that Gilead Sciences, Inc. will post -0.8 earnings per share for the current year.

Gilead Sciences Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, June 29th. Stockholders of record on Monday, June 15th will be paid a dividend of $0.82 per share. The ex-dividend date of this dividend is Monday, June 15th. This represents a $3.28 annualized dividend and a dividend yield of 2.7%. Gilead Sciences’s dividend payout ratio (DPR) is presently 44.69%.

Analysts Set New Price Targets

Several analysts recently weighed in on GILD shares. Citigroup upped their price objective on Gilead Sciences from $156.00 to $165.00 and gave the stock a “buy” rating in a research report on Monday, April 13th. Morgan Stanley decreased their target price on Gilead Sciences from $175.00 to $168.00 in a research report on Friday, May 8th. Maxim Group raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $165.00 target price for the company in a research note on Wednesday, May 20th. The Goldman Sachs Group increased their target price on shares of Gilead Sciences from $125.00 to $130.00 and gave the stock a “neutral” rating in a report on Friday, April 17th. Finally, Rothschild & Co Redburn reduced their price target on shares of Gilead Sciences from $170.00 to $167.00 in a research note on Monday, May 11th. Twenty-five investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $158.41.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.